ANDRX (ADRX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ANDRX (ADRX)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Dave K who wrote (110)	2/15/2000 3:14:00 PM
From: Dave K	Read Replies (1) of 127

RESEARCH ALERT- Andrx outperform repeated Tuesday February 15, 2:12 pm Eastern Time CHICAGO, Feb 15 (Reuters) - Gruntal & Co. said Tuesday it repeated its outperform rating on the intermediate and long term for Andrx Corp. after the drug company filed for marketing approval for the first generic version of Claritin, Schering-Plough Corp.'s (NYSE:SGP - news) blockbuster allergy drug. If approved, Andrx would have 180 days to market the drug exclusively. Gruntal also repeated intermediate and long term price targets of $86 and $96, respectively. Shares of Florida-based Andrx were up 2-1/8 to 71 in afternoon trade.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next